|1.29|| +0.04 / +3.20%|
Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It has active development programs which comprises of ongoing phase 2 trial of HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; ongoing phase 2 trial of novel antifungal VL-2397, for the treatment of patients with invasive aspergillosis; and early stage development program of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.
|Vijay B. Samant||President, Chief Executive Officer & Director|
|Keith D. Hall||Vice President-Operations|
|Anthony Alan Ramos||Chief Financial & Accounting Officer|
|Larry Smith||Senior Vice President-Research|
|Mammen P. Mammen||Senior Vice President-Clinical Development|